Developer docs
API playgroundTry for free, no card

Search company profiles

Inito

Full company profile

uuid0000o1k

Namestring
Inito
Legal namestring
Inito Health Inc.
Websiteurl
inito.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Inito is a privately held health-diagnostics company that develops and sells an at-home, smartphone-connected fertility monitoring system. Its core product, the Inito Fertility Monitor, pairs a proprietary optical reader — either the legacy First Generation Reader (iOS-attached) or the newer InSight Wireless Reader (standalone, Wi-Fi, iOS and Android) — with disposable immunoassay test strips and a companion mobile app. The system quantitatively measures four reproductive hormones (LH, Estrogen, PdG, and FSH) on independent tracks using Inito's proprietary Spectral Mapping™ technology, which combines fluorescence and colorimetric imaging, and applies AI/ML trained on more than 40 million hormone data points to deliver personalized cycle interpretation and ovulation confirmation rather than the faint-line, population-average thresholds of conventional ovulation predictor kits. The platform is FDA-registered, validated in peer-reviewed journals (Nature Scientific Reports and Human Reproduction Open, both 2023), and supported by 20+ patents.

Inito generates revenue through a hardware-plus-consumable model: the Inito Starter Kit (reader + 15 test strips) is sold for $119 (launch price, down from $169) via the company's own e-commerce storefront and authorized retailers including Amazon, with HSA/FSA eligibility and US shipping; recurring revenue comes from $49, 15-strip refill packs available as one-time purchases or auto-reorder subscriptions. Its primary customer segment is women trying to conceive (TTC), with targeted use cases for PCOS, advanced maternal age (35+), irregular cycles, post-miscarriage recovery, and couples weighing IVF. Marketing is content-led and community-driven, anchored by an SEO-rich blog, use-case landing pages, an active Facebook support group, and endorsements from named OB/GYNs and reproductive endocrinologists.

Following a $29 million Series B in December 2025 (led by Bertelsmann India Investments with Fireside Ventures and Kyra Ventures), Inito is extending the platform from fertility into a broader at-home hormone and health diagnostics platform powered by AI-engineered synthetic antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins. The company is incorporated in the United States as Inito Health Inc. (Houston, TX legal entity) and operates across Bengaluru (India), Dubai (UAE), and London (UK), having raised approximately $45 million in total disclosed equity funding.

Short descriptiontext

Inito is a privately held health-diagnostics company that sells an FDA-registered, smartphone-connected at-home fertility monitor measuring four hormones (LH, Estrogen, PdG, FSH) via proprietary optical and AI technology, serving women trying to conceive globally through a hardware-plus-consumable subscription model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home fertility monitoring, hormone tracking devices, consumer medical diagnostics, smartphone-connected diagnostics, reproductive health technology
Industry5 codes
PRIMARYHLALAHAA
Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYCRACAQAJ
Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAHAC
Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Family Planning Centers621410
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
At-Home Fertility Monitoring Devices
Social media profiles1 record
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware sales (Inito Fertility Monitor)
TypeHardware Sales
Description

One-time device purchase: Inito Starter Kit (InSight Wireless Reader + 15 Fertility Strips) at $119 (launch price, down from $169) or First Generation Reader kit at $99 (down from $149). HSA/FSA eligible.

inito.com
2Consumable test strip refills
TypeSubscription Recurring
Description

Recurring purchase of 15-strip refill packs at $49 each, available both as one-time orders and as subscriptions with auto-reorder and discount pricing.

inito.com
3Promotional codes and discounts
TypeTransaction Fee
Description

Discount codes (e.g., INITONG offering $50 off) used to drive conversion; promotional cards and codes are subject to separately published terms.

inito.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details3 tiers
1Inito Starter Kit – InSight Wireless Reader + 15 Fertility Strips
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$119 launch price (was $169); includes Wireless Reader with Wi-Fi, compatible with iOS & Android, Spectral Mapping technology; $50 off with code INITONG.

inito.com
2Inito Starter Kit – First Generation Reader + 15 Fertility Strips
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$99 (was $149); First Generation Reader attaches to phone, iOS only; $50 off with code INITONG.

inito.com
3Refill Pack – 15 Fertility Strips
ModelSubscriptionBilling cadenceMonthly
Notes

$49 per pack of 15 strips; can be ordered as one-time purchase or auto-reorder subscription; subscription orders include free return shipping on first two returns.

inito.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Inito designs, manufactures, and sells an at-home fertility monitoring ecosystem consisting of a proprietary smartphone-connected optical reader (InSight Wireless Reader or First Generation Reader), disposable immunoassay test strips that quantitatively measure four reproductive hormones (LH, Estrogen, PdG, FSH), and a companion mobile app that uses computer vision and AI to interpret results. The kit confirms ovulation and identifies a personalized six-day fertile window, with consumable strip refills sold on a subscription basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Trusted by 200,000+ couples worldwide
+5 more records
Product overview1 text field

Inito operates a single-product platform centered on the Inito Fertility Monitor, an FDA-registered medical device ecosystem consisting of two interchangeable hardware readers (the new InSight Wireless Reader™ and the legacy First Generation Reader), a consumable Inito Fertility Strips refill line (sold on subscription), the Inito Fertility & Ovulation mobile app for iOS and Android that runs the AI interpretation engine, and complementary offerings such as the InTemp Basal Thermometer and an opt-in Fertility Coach service. The hardware/software bundle uses Inito's proprietary Spectral Mapping™ computer-vision technology combined with on-device AI trained on more than 40 million hormone data points to deliver lab-grade quantitative measurements of four fertility hormones. Following the December 2025 Series B raise, Inito is expanding this core platform into a broader at-home hormone and health diagnostics platform powered by AI-engineered (synthetic) antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins.

Product and service7 records
1Inito Fertility Monitor (Starter Kit)
CategoryCore fertility monitoring hardware
Description

The flagship at-home fertility monitoring kit that pairs a smartphone-connected reader with disposable test strips to quantitatively measure four hormones (LH, Estrogen, PdG, FSH) in urine and confirm ovulation within approximately 10 minutes; sold direct-to-consumer with HSA/FSA eligibility and free US shipping.

2InSight Wireless Reader
CategoryHardware reader
Description

New-generation wireless reader compatible with both iOS and Android, featuring enhanced precision via Inito Spectral Mapping technology and standalone Wi-Fi connectivity; pairs with the Inito app to display hormone values and personalized insights.

3First Generation Reader
CategoryHardware reader (legacy)
Description

The original Inito reader that attaches physically to an iOS phone and functions only while connected; sold at a reduced legacy price compared to the InSight Wireless Reader.

4Inito Fertility Strips (15-strip refill pack)
CategoryConsumable test strips
Description

Single-use refill strips for use with either Inito reader; each strip simultaneously measures PdG (to confirm ovulation), Estrogen and LH (to predict the fertile window), and FSH (to track follicle growth); available as subscription refills at $49 per 15-strip pack.

5Inito Fertility & Ovulation App (iOS/Android)
CategoryMobile software / companion app
Description

Companion mobile app that connects to the Inito reader, applies AI to interpret captured strip images, displays trend charts and personalized fertility insights, and lets users log symptoms, sex, medications, and pregnancy tests; no paid subscription required.

6InTemp Basal Thermometer
CategoryCompanion hardware device
Description

Companion basal thermometer covered under the Inito 1-year limited warranty; sold as part of the Inito product ecosystem for users tracking basal body temperature alongside hormone data.

7Inito Fertility Coach
CategoryCoaching service / add-on
Description

Opt-in human coaching service referenced in the Terms of Service; users can elect to work with a Fertility Coach via email, chat, or calls to interpret their hormone data. Inito disclaims creation of any doctor-patient relationship through this service.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1DC Advisory
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-12-12
Description

Served as financial advisor to Inito on its Series B fundraise from Bertelsmann India Investments, Fireside Ventures, and Kyra Ventures (transaction closed December 2025).

dcadvisory.com
2Dr. Danielle Jones (Board-certified OB/GYN, @mamamdj)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Featured clinician endorser on the Inito homepage with 1.4M+ subscribers; provides video testimonial that Inito tracks multiple hormones in real time versus OPKs and BBT.

inito.com
3Inito Clinical Advisors (Dr. Bradford Bopp, Dr. Robert Colver, Dr. Schehrezade Khan, Dr. Abhi Shahi, Dr. Prem Pillay, Dr. Sailaja M. Blackmon)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Six named clinical advisors (MDs / FRCS / FACS) listed on the About Inito page, lending medical expertise and credibility to product development and clinical positioning.

inito.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Tempdrop is a wearable basal body temperature sensor for cycle and fertility tracking. It serves an overlapping TTC audience with a different modality and price point, and competes for the same consumer wallet on the fertility tracking journey.

TypeEmerging player
Description

Oura's smart ring tracks physiological markers and integrates with several women's health apps, including cycle and pregnancy features. While it does not directly measure hormones like Inito, it represents an emerging wearable-led path to fertility insights that could partially substitute for a dedicated monitor.

TypeDirect peer
Description

Mira sells a smartphone-connected hormone monitor and quantitative ovulation and fertility test strips. Like Inito, it positions on lab-grade multi-hormone measurement (LH, E3G, PdG) at home with AI-driven cycle insights, making it the closest direct competitor in the connected fertility monitor category.

TypeBroad incumbent
Description

Clearblue is the dominant incumbent brand of home ovulation and pregnancy tests, sold globally through retail. It competes with Inito on the entry-level OPK shelf and sets the price/availability benchmark Inito must beat to convert first-time buyers.

TypeDirect peer
Description

Proov is best known for the first at-home PdG ovulation confirmation test and has expanded into a multi-hormone test strip line. It overlaps directly with Inito's PdG-based ovulation confirmation and multi-hormone value proposition for the same trying-to-conceive customer.

TypeDirect peer
Description

Modern Fertility, now part of Ro, sells at-home hormone tests and a fertility tracking experience targeted at women planning pregnancy or assessing fertility. It overlaps with Inito's expansion thesis into broader reproductive hormone diagnostics beyond a single monitor.

TypeBroad incumbent
Description

First Response is a mass-market incumbent in home pregnancy and ovulation testing, with deep retail distribution. It competes with Inito in the broader 'track and confirm ovulation' use case and represents the low-cost retail alternative Inito must outperform on data quality.

TypeDirect peer
Description

Natural Cycles is an FDA-cleared app-driven fertility tracking product that combines basal body temperature with algorithm-based cycle predictions. It competes with Inito for the same TTC consumer but solves the problem with software and a thermometer rather than a hormone test strip, and is an obvious adjacent play for Inito to integrate or compete against.

TypeEmerging player
Description

Eli Health is an emerging at-home hormone testing startup building continuous and instant hormone monitoring products. Its mission to bring multi-hormone home diagnostics overlaps with Inito's announced expansion into broader hormone and biomarker testing.

10Ava
TypeDirect peer
Description

Ava sells a fertility tracking wearable bracelet and companion app that uses physiological signals to predict the fertile window. It targets the same TTC audience as Inito with a hardware-plus-subscription model, but with a different sensing modality (wrist-worn sensors vs urine test strips).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inito

At-Home Fertility Monitoring Devicesinito.com

Inito is a privately held health-diagnostics company that sells an FDA-registered, smartphone-connected at-home fertility monitor measuring four hormones (LH, Estrogen, PdG, FSH) via proprietary optical and AI technology, serving women trying to conceive globally through a hardware-plus-consumable subscription model.

What Inito does

Inito is a privately held health-diagnostics company that develops and sells an at-home, smartphone-connected fertility monitoring system. Its core product, the Inito Fertility Monitor, pairs a proprietary optical reader — either the legacy First Generation Reader (iOS-attached) or the newer InSight Wireless Reader (standalone, Wi-Fi, iOS and Android) — with disposable immunoassay test strips and a companion mobile app. The system quantitatively measures four reproductive hormones (LH, Estrogen, PdG, and FSH) on independent tracks using Inito's proprietary Spectral Mapping™ technology, which combines fluorescence and colorimetric imaging, and applies AI/ML trained on more than 40 million hormone data points to deliver personalized cycle interpretation and ovulation confirmation rather than the faint-line, population-average thresholds of conventional ovulation predictor kits. The platform is FDA-registered, validated in peer-reviewed journals (Nature Scientific Reports and Human Reproduction Open, both 2023), and supported by 20+ patents.

Inito generates revenue through a hardware-plus-consumable model: the Inito Starter Kit (reader + 15 test strips) is sold for $119 (launch price, down from $169) via the company's own e-commerce storefront and authorized retailers including Amazon, with HSA/FSA eligibility and US shipping; recurring revenue comes from $49, 15-strip refill packs available as one-time purchases or auto-reorder subscriptions. Its primary customer segment is women trying to conceive (TTC), with targeted use cases for PCOS, advanced maternal age (35+), irregular cycles, post-miscarriage recovery, and couples weighing IVF. Marketing is content-led and community-driven, anchored by an SEO-rich blog, use-case landing pages, an active Facebook support group, and endorsements from named OB/GYNs and reproductive endocrinologists.

Following a $29 million Series B in December 2025 (led by Bertelsmann India Investments with Fireside Ventures and Kyra Ventures), Inito is extending the platform from fertility into a broader at-home hormone and health diagnostics platform powered by AI-engineered synthetic antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins. The company is incorporated in the United States as Inito Health Inc. (Houston, TX legal entity) and operates across Bengaluru (India), Dubai (UAE), and London (UK), having raised approximately $45 million in total disclosed equity funding.

Inito firmographics

Firmographics
Name
Inito
Legal name
Inito Health Inc.
Website
https://inito.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
Inito is a privately held health-diagnostics company that sells an FDA-registered, smartphone-connected at-home fertility monitor measuring four hormones (LH, Estrogen, PdG, FSH) via proprietary optical and AI technology, serving women trying to conceive globally through a hardware-plus-consumable subscription model.
Ownership category
akta.pro rank

Inito industry classification

Industry
Product category
At-Home Fertility Monitoring Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Family Planning Centers (621410)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLALAHAA
Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYCRACAQAJ
Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAHAC
Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)

Keywords

  • At-home fertility monitoring
  • Hormone tracking devices
  • Consumer medical diagnostics
  • Smartphone-connected diagnostics
  • Reproductive health technology

Where Inito is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Inito business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Hardware sales (Inito Fertility Monitor): One-time device purchase: Inito Starter Kit (InSight Wireless Reader + 15 Fertility Strips) at $119 (launch price, down from $169) or First Generation Reader kit at $99 (down from $149). HSA/FSA eligible.
  2. Consumable test strip refills: Recurring purchase of 15-strip refill packs at $49 each, available both as one-time orders and as subscriptions with auto-reorder and discount pricing.
  3. Promotional codes and discounts: Discount codes (e.g., INITONG offering $50 off) used to drive conversion; promotional cards and codes are subject to separately published terms.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goInito Starter Kit – InSight Wireless Reader + 15 Fertility Strips
One time/ perpetual licensePay-as-you-goInito Starter Kit – First Generation Reader + 15 Fertility Strips
SubscriptionMonthlyRefill Pack – 15 Fertility Strips

Go-to-market motion5 records

Distribution channels3 records

Marketing channels8 records

Inito product offering

Product offering

Core offering

Inito designs, manufactures, and sells an at-home fertility monitoring ecosystem consisting of a proprietary smartphone-connected optical reader (InSight Wireless Reader or First Generation Reader), disposable immunoassay test strips that quantitatively measure four reproductive hormones (LH, Estrogen, PdG, FSH), and a companion mobile app that uses computer vision and AI to interpret results. The kit confirms ovulation and identifies a personalized six-day fertile window, with consumable strip refills sold on a subscription basis.

Product overview

Inito operates a single-product platform centered on the Inito Fertility Monitor, an FDA-registered medical device ecosystem consisting of two interchangeable hardware readers (the new InSight Wireless Reader™ and the legacy First Generation Reader), a consumable Inito Fertility Strips refill line (sold on subscription), the Inito Fertility & Ovulation mobile app for iOS and Android that runs the AI interpretation engine, and complementary offerings such as the InTemp Basal Thermometer and an opt-in Fertility Coach service. The hardware/software bundle uses Inito's proprietary Spectral Mapping™ computer-vision technology combined with on-device AI trained on more than 40 million hormone data points to deliver lab-grade quantitative measurements of four fertility hormones. Following the December 2025 Series B raise, Inito is expanding this core platform into a broader at-home hormone and health diagnostics platform powered by AI-engineered (synthetic) antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins.

Differentiator

Problem solved

Functional benefit

Products and services

  • Inito Fertility Monitor (Starter Kit) The flagship at-home fertility monitoring kit that pairs a smartphone-connected reader with disposable test strips to quantitatively measure four hormones (LH, Estrogen, PdG, FSH) in urine and confirm ovulation within approximately 10 minutes; sold direct-to-consumer with HSA/FSA eligibility and free US shipping.
  • InSight Wireless Reader New-generation wireless reader compatible with both iOS and Android, featuring enhanced precision via Inito Spectral Mapping technology and standalone Wi-Fi connectivity; pairs with the Inito app to display hormone values and personalized insights.
  • First Generation Reader The original Inito reader that attaches physically to an iOS phone and functions only while connected; sold at a reduced legacy price compared to the InSight Wireless Reader.
  • Inito Fertility Strips (15-strip refill pack) Single-use refill strips for use with either Inito reader; each strip simultaneously measures PdG (to confirm ovulation), Estrogen and LH (to predict the fertile window), and FSH (to track follicle growth); available as subscription refills at $49 per 15-strip pack.
  • Inito Fertility & Ovulation App (iOS/Android) Companion mobile app that connects to the Inito reader, applies AI to interpret captured strip images, displays trend charts and personalized fertility insights, and lets users log symptoms, sex, medications, and pregnancy tests; no paid subscription required.
  • InTemp Basal Thermometer Companion basal thermometer covered under the Inito 1-year limited warranty; sold as part of the Inito product ecosystem for users tracking basal body temperature alongside hormone data.
  • Inito Fertility Coach Opt-in human coaching service referenced in the Terms of Service; users can elect to work with a Fertility Coach via email, chat, or calls to interpret their hormone data. Inito disclaims creation of any doctor-patient relationship through this service.

Quantifiable outcome

  • Trusted by 200,000+ couples worldwide
  • +5 more outcomes

Companies that use Inito

Customer profile

Segments7 records

Ideal customer profiles2 records

Inito technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature6 records

Inito partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • DC AdvisoryminorImplementation/ SI/ Consulting Partner · 12 December 2025Served as financial advisor to Inito on its Series B fundraise from Bertelsmann India Investments, Fireside Ventures, and Kyra Ventures (transaction closed December 2025).
  • Dr. Danielle Jones (Board-certified OB/GYN, @mamamdj)coreGTM or Marketing PartnerFeatured clinician endorser on the Inito homepage with 1.4M+ subscribers; provides video testimonial that Inito tracks multiple hormones in real time versus OPKs and BBT.
  • Inito Clinical Advisors (Dr. Bradford Bopp, Dr. Robert Colver, Dr. Schehrezade Khan, Dr. Abhi Shahi, Dr. Prem Pillay, Dr. Sailaja M. Blackmon)coreStrategic or Co-development PartnerSix named clinical advisors (MDs / FRCS / FACS) listed on the About Inito page, lending medical expertise and credibility to product development and clinical positioning.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Inito competitors and assessment

Company assessment

Emerging players

  • Tempdrop: Tempdrop is a wearable basal body temperature sensor for cycle and fertility tracking. It serves an overlapping TTC audience with a different modality and price point, and competes for the same consumer wallet on the fertility tracking journey.
  • Oura: Oura's smart ring tracks physiological markers and integrates with several women's health apps, including cycle and pregnancy features. While it does not directly measure hormones like Inito, it represents an emerging wearable-led path to fertility insights that could partially substitute for a dedicated monitor.
  • Eli Health: Eli Health is an emerging at-home hormone testing startup building continuous and instant hormone monitoring products. Its mission to bring multi-hormone home diagnostics overlaps with Inito's announced expansion into broader hormone and biomarker testing.

Direct peers

  • Mira: Mira sells a smartphone-connected hormone monitor and quantitative ovulation and fertility test strips. Like Inito, it positions on lab-grade multi-hormone measurement (LH, E3G, PdG) at home with AI-driven cycle insights, making it the closest direct competitor in the connected fertility monitor category.
  • Proov: Proov is best known for the first at-home PdG ovulation confirmation test and has expanded into a multi-hormone test strip line. It overlaps directly with Inito's PdG-based ovulation confirmation and multi-hormone value proposition for the same trying-to-conceive customer.
  • Modern Fertility (Ro): Modern Fertility, now part of Ro, sells at-home hormone tests and a fertility tracking experience targeted at women planning pregnancy or assessing fertility. It overlaps with Inito's expansion thesis into broader reproductive hormone diagnostics beyond a single monitor.
  • Natural Cycles: Natural Cycles is an FDA-cleared app-driven fertility tracking product that combines basal body temperature with algorithm-based cycle predictions. It competes with Inito for the same TTC consumer but solves the problem with software and a thermometer rather than a hormone test strip, and is an obvious adjacent play for Inito to integrate or compete against.
  • Ava: Ava sells a fertility tracking wearable bracelet and companion app that uses physiological signals to predict the fertile window. It targets the same TTC audience as Inito with a hardware-plus-subscription model, but with a different sensing modality (wrist-worn sensors vs urine test strips).

Broad incumbents

  • Clearblue: Clearblue is the dominant incumbent brand of home ovulation and pregnancy tests, sold globally through retail. It competes with Inito on the entry-level OPK shelf and sets the price/availability benchmark Inito must beat to convert first-time buyers.
  • First Response: First Response is a mass-market incumbent in home pregnancy and ovulation testing, with deep retail distribution. It competes with Inito in the broader 'track and confirm ovulation' use case and represents the low-cost retail alternative Inito must outperform on data quality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Inito social profiles

Digital presence

Inito compliance and trust

Trust signal

Compliance4 records

Inito financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inito leadership team

Management profile

Number of profiles

Profiles8 records

Inito funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inito M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inito

What does Inito do?

Inito designs, manufactures, and sells an at-home fertility monitoring ecosystem consisting of a proprietary smartphone-connected optical reader (InSight Wireless Reader or First Generation Reader), disposable immunoassay test strips that quantitatively measure four reproductive hormones (LH, Estrogen, PdG, FSH), and a companion mobile app that uses computer vision and AI to interpret results. The kit confirms ovulation and identifies a personalized six-day fertile window, with consumable strip refills sold on a subscription basis.

Is Inito a public or private company?

Inito is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inito founded?

Inito was founded in 2021. It employs 251 to 500 people.

Where is Inito based?

Inito is headquartered in Houston, United States, in the North America region.

How does Inito make money?

Three revenue lines are on record. Hardware sales (Inito Fertility Monitor) is the primary driver. The others are consumable test strip refills and promotional codes and discounts.

Who are Inito's main competitors?

Emerging players on record are Tempdrop, Oura and Eli Health. Direct peers are Mira, Proov, Modern Fertility (Ro), Natural Cycles and Ava. Broad incumbents are Clearblue and First Response.

Does Inito have an API?

No public API is recorded for Inito.

What industry is Inito in?

Inito's product category is At-Home Fertility Monitoring Devices. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogInito Launches InSight Wireless Reader, the Most Precise At-Home Fertility Reader, Trained on Over 40M DatapointsInito launched InSight Wireless Reader, a Wi-Fi enabled fertility hormone reader measuring estrogen, LH, PdG, and FSH on a single strip. The device uses patented Spectral Mapping technology and is priced at $99 with 15 strips included. It is compatible with iOS and Android.Crunchbase News5 Interesting Startup Deals You May Have Missed In December: A Hospital-Grade Wireless Heart Monitor, AI-Designed Proteins For Manufacturing, And MoreIn December, several startups secured funding, including Inito, which raised $29 million to expand its at-home hormone health testing platform; Assaia, which received $26.6 million to enhance its AI-driven airport operations technology; and Wearlinq, which announced a $14 million Series A for its wireless heart monitor. The funding aims to support advancements in at-home diagnostics, airport efficiency, and cardiac monitoring technologies. These investments reflect a significant trend in innovative solutions across various sectors.FittInito Raises $29M for At-Home Fertility DiagnosticsFertility startup Inito has raised $29 million to scale its at-home diagnostics platform, which uses AI to analyze urine-based strips for ovulation prediction. The company aims to develop AI-engineered antibodies to enhance test accuracy and expand into a full-spectrum hormone health platform covering pregnancy and menopause. This funding positions Inito within a growing market of competitors leveraging hormonal data for autonomous fertility care.StartupstorymediaIndian home diagnostics firm Inito raises $29m series BIndian home diagnostics startup Inito has raised $29 million in a Series B round to expand its AI-powered home testing platform. This funding will enable Inito to broaden its product offerings to include a variety of hormone and health diagnostics while strengthening its manufacturing and regulatory capabilities. The company aims to position itself as a full-stack at-home diagnostics platform, moving beyond its initial focus on fertility testing.The Times of IndiaETtech Deals Digest: Startups raise $375 million this week, up 15% on-yearIndian startups raised $375.2 million across 23 deals between December 6 and 12, marking a 15% year-on-year increase in funding volume despite a decline in deal count. Key transactions included Harness securing $240 million to reach a $5.5 billion valuation, Fibe raising $35 million from the IFC, and Inito obtaining $29 million led by Bertelsmann India Investments.InitoInito raises $29M to expand beyond fertility and advance at-home diagnostics powered by AI-engineered antibodiesBengaluru-based health diagnostics company Inito has raised $29 million in Series B funding, led by Bertelsmann India Investments and co-led by Fireside Ventures, bringing its total equity funding to $45 million. The company, which launched its fertility monitor in 2021 and has since analyzed over 30 million hormone data points while supporting tens of thousands of pregnancies, will use the capital to expand from fertility diagnostics into a broader at-home health diagnostics platform powered by AI-engineered antibodies. The funding accelerates Inito's shift toward computational protein design that enables synthetic antibodies more sensitive and consistent than traditional animal-based methods.Tracxn2025 Company Profile, Team, Funding, Competitors & FinancialsInito, a provider of at-home fertility monitoring systems and women's health software, has raised a total of $45 million across 11 funding rounds. Its latest financing was a Series B round of $29 million on December 10, 2025, led by Bertelsmann India Investments. The company reported having 819 employees as of August 2025.RedditHas anyone used Inito Fertility? : rA Reddit user is seeking community feedback on the legitimacy and effectiveness of the Inito Fertility Kit, an at-home ovulation monitoring device. The inquiry was prompted by targeted advertising and conflicting information regarding the product's reliability compared to Amazon reviews.IncubeesInito raises $29M in Series B, led by Bertelsmann India Investments, to advance at-home diagnostics powered by AI-engineered antibodies – IncubeesInito, a health diagnostics company based in India, announced it raised $29 million in Series B funding led by Bertelsmann India Investments to expand beyond fertility diagnostics into broader at-home health testing powered by AI-engineered antibodies.